MEK inhibition and immune responses in advanced melanoma

MEK inhibition and immune responses in advanced melanoma

phase II and III clinical trials demonstrated modest anti- tumor activity of Binimetinib (MEK162) - a potent allosteric inhibitor of MEK1 and MEK2- in patients with advanced NRAS mutant melanoma. The analysis of the NEMO study in NRAS mutated melanoma, has shown that pre-treatment with immunotherapy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncoimmunology 2017-08, Vol.6 (8), p.e1335843-e1335843
Hauptverfasser: Dummer, Reinhard, Ramelyte, Egle, Schindler, Sabrina, Thürigen, Olaf, Levesque, Mitchell P., Koelblinger, Peter
Format: Artikel
Sprache:eng
Schlagworte:
BRAF mutation
immunogenicity
immunotherapy
MEK inhibitors
MEK kinase pathway
Melanoma
NRAS mutation
Review
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:phase II and III clinical trials demonstrated modest anti- tumor activity of Binimetinib (MEK162) - a potent allosteric inhibitor of MEK1 and MEK2- in patients with advanced NRAS mutant melanoma. The analysis of the NEMO study in NRAS mutated melanoma, has shown that pre-treatment with immunotherapy improved the outcome of binimetinib therapy. We discuss this finding in the context of in vitro and in vivo effects of MEK inhibition on immuno-critical pathways and interactions.
ISSN:2162-4011
2162-402X
2162-402X
DOI:10.1080/2162402X.2017.1335843